Cadrenal Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Cadrenal Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $80.10K, a 93.48% decline year-over-year.
- Cadrenal Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $1.30M, a 33.88% decline year-over-year.
- Cadrenal Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $759.54K, a 76.83% decline year-over-year.
- Cadrenal Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $632.35K, a 58.61% decline year-over-year.
- Cadrenal Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2025 was $4.59M, a 4.48% decline from fiscal 2024.
- Cadrenal Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2024 was $4.81M, a 11.14% decline from fiscal 2023.
- Cadrenal Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $5.41M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $80.10K 10-Q · filed 2026-08-13 | $2.77M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.30M 10-Q · filed 2026-05-07 | $3.92M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $759.54K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $4.59M 10-K · filed 2026-03-31 |
| 2025-09-30 | $632.35K 10-Q · filed 2025-11-10 | $7.11M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.23M 10-Q · filed 2026-08-13 | $8.00M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.97M 10-Q · filed 2026-05-07 | |
| 2024-12-31 | $3.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $4.81M 10-K · filed 2026-03-31 |
| 2024-09-30 | $1.53M 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $5.41M 10-K · filed 2025-03-13 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | |
| 2023-03-31 | $5.41M 10-Q · filed 2024-05-09 | |
| 2022-06-30 | $450.00 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |